Madrigal Pharmaceuticals, Inc.
Clinical trials sponsored by Madrigal Pharmaceuticals, Inc., explained in plain language.
A biopharmaceutical company developing therapies for liver diseases, including NASH.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to stop liver failure in NASH patients Results expected Dec 2026 (estimated) May already have reported ↗
- New pill shows promise for fatty liver in major trial Results expected Mar 2027 (estimated) May already have reported ↗